Bempedoic Acid

Esperion Therapeutics Inc (NASDAQ: ESPR) stock lost roughly a third of its value Wednesday after the company reported mixed Phase III results for its leading drug candidate, bempedoic acid. While the company hit its primary endpoints with the trial, patients in the test group experienced a higher...

Takeover chatter prompted a 5.5 percent spike in Esperion Therapeutics Inc (NASDAQ: ESPR) Monday. A source familiar with the matter told Benzinga the cholesterol-focused pharmaceutical could be drawing interest from a player in the cardiovascular space. The reaction follows a Friday Seeking Alpha...